BridgeBio Pharma, Inc. is making strides in the realm of genetic disease treatments. The company boasts a vast pipeline of 30 development programs, ranging from early exploration to late-stage development. Among its products in development include AG10 and BBP-265, which are small molecule stabilizers of transthyretin (TTR) and are undergoing Phase 3 clinical trials for the treatment of TTR amyloidosis-cardiomyopathy (ATTR-CM). Meanwhile, BBP-831, a selective FGFR1-3 inhibitor, is undergoing Phase 2 clinical trials to treat achondroplasia in pediatric patients, with BBP-631, an AAV5 gene transfer product candidate, undergoing Phase 2 clinical trials for the treatment of congenital adrenal hyperplasia (CAH) driven by 21-hydroxylase deficiency (21OHD). Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR), is undergoing Phase 2 proof-of-concept clinical trials for Autosomal Dominant Hypocalcemia Type 1 (ADH1), while BBP-711 is being developed for the treatment of hyperoxaluria and patients suffering from recurrent kidney stones. BridgeBio Pharma, Inc. is also exploring products for Mendelian, oncology, and gene therapy diseases. In terms of partnerships, the company has license and collaboration agreements with esteemed organizations such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. BridgeBio Pharma, Inc. was established in 2015 and headquartered in Palo Alto, California.
BridgeBio Pharma's ticker is BBIO
The company's shares trade on the NASDAQ stock exchange
They are based in Palo Alto, California
There are 201-500 employees working at BridgeBio Pharma
It is bridgebio.com
BridgeBio Pharma is in the Healthcare sector
BridgeBio Pharma is in the Biotechnology industry
The following five companies are BridgeBio Pharma's industry peers: